{"id":2097,"date":"2018-11-08T12:57:05","date_gmt":"2018-11-08T12:57:05","guid":{"rendered":"http:\/\/edren.org\/ren\/?page_id=2097"},"modified":"2018-12-21T13:38:14","modified_gmt":"2018-12-21T13:38:14","slug":"innovations-and-research","status":"publish","type":"page","link":"https:\/\/edren.org\/ren\/unit\/history\/innovations-and-research\/","title":{"rendered":"Innovations and research"},"content":{"rendered":"<p>Innovations and research areas related to Renal Medicine or Transplantation in Edinburgh in the 1960s to 1990s<\/p>\n<h5><strong><span style=\"color: #993300;\">New inventions:<\/span><\/strong><\/h5>\n<p>1961 Fluon arterio-venous shunt for repeated haemodialysis, by Mr I Sinclair, Mr M Henderson and Dr D Simpson (Sinclair et al, 1961)<br \/>\n1964 Regional heparinisation developed by Dr Howard Davies, haematologist at RIE<\/p>\n<h5><strong><span style=\"color: #993300;\">Main research areas:<\/span><\/strong><\/h5>\n<p>site of action of diuretics (references 1- 3)<br \/>\neffects of potassium depletion on the kidney (reference 4)<br \/>\nacid-base disequilibrium in dialysed patients (reference 5)<br \/>\ntreatment of minimal lesion glomerulonephritis with steroids (reference 6)<br \/>\nnature of protein in glomerulonephritis (references 7- 9)<br \/>\nnature of glomerular disease (references 10, 11)<br \/>\nfibrin-degradation products in patients with renal disease (reference 12)<br \/>\naluminium-induced anaemia, aluminium-induced bone disease and other effects of aluminium in dialysis patients (references 13-17)<br \/>\neffects of nephrectomy on anaemia in patients with chronic renal disease (reference 18)<br \/>\nplasma exchange programme for treating severe renal disease (references 19-21)<br \/>\nprostaglandin levels during sodium chloride infusion (reference 22)<br \/>\nkallikrein-kinin and rennin-angiotensin systems in nephrotic syndrome (references 23-25)<br \/>\nother studies on prostaglandins and kallikrein (references 26-29)<br \/>\nperitoneal dialysis (references 30, 31)<br \/>\ndevelopment of the first successful recombinant vaccine against the hepatitis B virus (reference 32)<br \/>\ndevelopment of techniques for producing transgenic mice (reference 33)<br \/>\ntumour immunology (references 34, 35)<br \/>\ntransplantation immunology, including the mode of action of anti-lymphocyte globulins (ALG), the aspect of immune response suppressed by ALG and the nature of ALG and application of ALG to human renal transplantation (references 36-39)<br \/>\nhuman renal transplantation (references 40-44)<\/p>\n<h5><strong><span style=\"color: #993300;\">References for main research areas:<\/span><\/strong><\/h5>\n<p><span style=\"font-size: 12pt;\">1. Robson JS et al. The effect of chlorothiazide in diabetes insipidus with particular reference to the osmolality of the serum. Metabolism. 1962; 1: 1041-53.<\/span><br \/>\n<span style=\"font-size: 12pt;\">2. Lambie AT et al. The effect of mersalyl on the renal tubular reabsorption of solute free water. Clinical science. 1961; 20: 123-9.<\/span><br \/>\n<span style=\"font-size: 12pt;\">3. Fraser AG et al. The effects of furosemide on the osmolality of the urine and the composition of renal tissue. Journal of Pharmacology &amp; Experimental Therapeutics. 1967; 158: 475-86.<\/span><br \/>\n<span style=\"font-size: 12pt;\">4. MacDonald MK et al. The nephropathy pf experimental potassium deficiency. An electron microscopic study. Quarterly Journal of Experimental physiology. 1962; 47: 262-72.<\/span><br \/>\n<span style=\"font-size: 12pt;\">5. Lambie AT et al. Intracellular hydrogen ion concentration in renal acidosis. Clinical Science. 1965; 28: 237-49.<\/span><br \/>\n<span style=\"font-size: 12pt;\">6. MacDonald MK et al. Resolution of glomerular lesions in the nephrotic syndrome treated with cortisone: electron microscopic studies in an adult case. Scottish Medical Journal. 1959; 4: 415-21.<\/span><br \/>\n<span style=\"font-size: 12pt;\">7. Petrie JJ et al. Glomerular permeability to serum proteins and high molecular weight dextrans in glomerulonephritis. Clinical Science. 1968; 34: 83-95.<\/span><br \/>\n<span style=\"font-size: 12pt;\">8. Petrie JJ et al. Protein selectivity in the assessment of patients with proteinuria. Australian and New Zealand Journal of Medicine. 1973; 3: 480-5.<\/span><br \/>\n<span style=\"font-size: 12pt;\">9. Cumming AD et al. Significance of urinary C3 excretion in glomerulonephritis. Journal of Clinical Pathology. 1976; 29: 601-7.<\/span><br \/>\n<span style=\"font-size: 12pt;\">10. Petrie JJ et al. Glomerular permeability during proteinuria induced by plasma infusion. Clinical Science. 1970; 39: 383-9.<\/span><br \/>\n<span style=\"font-size: 12pt;\">11. Davison AM et al. The role of the mesangial cell in proliferative glomerulonephritis. Journal of Clinical Pathology. 1973; 26: 198-208.<\/span><br \/>\n<span style=\"font-size: 12pt;\">12. Clarkson AR et al. Serum and urinary fibrin-fibrinogen degradation products in glomerulonephritis. BMJ. 1971; 3: 447-51.<\/span><br \/>\n<span style=\"font-size: 12pt;\">13. Petrie JJ, Fleming R, McKinnon P, Winney RJ, Cowie J. The use of ion exchange to remove aluminium from water used in haemodialysis. American journal of kidney diseases. 1984; 4: 69-74.<\/span><br \/>\n<span style=\"font-size: 12pt;\">14. Winney RJ et al. Epidemiology of aluminium toxicity in a &#8216;low incidence&#8217; area. Contributions to Nephrology. 1984; 38: 47-58.<\/span><br \/>\n<span style=\"font-size: 12pt;\">15. Winney RJ et al. What is the value of plasma\/serum aluminum in patients with chronic renal failure? Clinical Nephrology. 1985; 24 Suppl 1: S2-8.<\/span><br \/>\n<span style=\"font-size: 12pt;\">16. Winney RJ et al. Role of plasma aluminum in the detection and prevention of aluminum toxicity. Kidney International 1986; 18 Suppl4: S91-5.<\/span><br \/>\n<span style=\"font-size: 12pt;\">17. Smith GD et al. Aluminium-related osteomalacia: response to reverse osmosis water treatment. Kidney International. 1987; 32: 96-101.<\/span><br \/>\n<span style=\"font-size: 12pt;\">18. Gibson P et al. Bilateral nephrectomy and haemodialysis for the treatment of severe loin pain haematuria syndrome. Nephrology, Dialysis, Transplantation. 1994; 9: 1640-1.<\/span><br \/>\n<span style=\"font-size: 12pt;\">19. Swainson CP et al. Plasma exchange in severe glomerulonephritis&#8211;who benefits? Proceedings of the European Dialysis and Transplant Association. 1983; 19: 732-7.<\/span><br \/>\n<span style=\"font-size: 12pt;\">20. Bell GM et al. Crescentic glomerulonephritis- which patients should be treated with plasma exchange? Life Support Systems. 1983; 1 Suppl 1: 92-4.<\/span><br \/>\n<span style=\"font-size: 12pt;\">21. Swainson CP et al. Treatment of Goodpasture&#8217;s disease by plasma exchange and immunosuppression. Clinical &amp; Experimental Immunology. 1978; 32: 233-42.<\/span><br \/>\n<span style=\"font-size: 12pt;\">22. Watson ML et al. Prostaglandins and kallikrein during volume expansion in normal man. Contributions to Nephrology. 1984; 41: 31-4.<\/span><br \/>\n<span style=\"font-size: 12pt;\">23. Cumming AD et al. The plasma kallikrein kinin system in severely ill and traumatised patients. Archives of Emergency Medicine. 1984; 1: 135-42.<\/span><br \/>\n<span style=\"font-size: 12pt;\">24. Cumming AD et al. Urinary kallikrein excretion in glomerulonephritis and nephrotic syndrome. Nephron. 1985; 39: 206-10.<\/span><br \/>\n<span style=\"font-size: 12pt;\">25. Cumming AD et al. The kallikrein-kinin and renin-angiotensin systems in nephrotic syndrome. Nephron. 1989; 51: 185-91.<\/span><br \/>\n<span style=\"font-size: 12pt;\">26. Watson ML et al. Role of prostaglandins in mediating excretion by the kidney of an intravenous infusion of sodium chloride in normal human subjects. Clinical Science. 1982; 62: 27-33.<\/span><br \/>\n<span style=\"font-size: 12pt;\">27. Mackay IG et al. Contribution of prostaglandins to the systemic and renal vascular response to frusemide in normal man. British Journal of Clinical Pharmacology. 1984; 17: 513-9.<\/span><br \/>\n<span style=\"font-size: 12pt;\">28. Watson ML et al. Prostaglandins and kallikrein during volume expansion in normal man. Contributions to Nephrology. 1984; 41: 31-4.<\/span><br \/>\n<span style=\"font-size: 12pt;\">29. Watson ML et al. Urinary kallikrein and systemic prostacyclin synthesis during sodium chloride infusion in normal man. Clinical Science. 1985; 68: 537-43.<\/span><br \/>\n<span style=\"font-size: 12pt;\">30. Cumming AD et al. Continuous ambulatory peritoneal dialysis in Edinburgh. Proceedings of the Royal College of Physicians of Edinburgh, Tercentenary Congress, 1981, pages 303-4.<\/span><br \/>\n<span style=\"font-size: 12pt;\">31. Cumming AD et al. Acute aluminium intoxication in patients on continuous ambulatory peritoneal dialysis. Lancet. 1982; 9: 103-4.<\/span><br \/>\n<span style=\"font-size: 12pt;\">32. Marmion BP. Prospects for new viral vaccines. Philosophical Transactions of the Royal Society of London &#8211; Series B: Biological Sciences. 1980; 290: 395-407.<\/span><br \/>\n<span style=\"font-size: 12pt;\">33. Hooper M et al. HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. Nature. 1987; 326 (6110): 292-5.<\/span><br \/>\n<span style=\"font-size: 12pt;\">34. James K et al. The effect of Corynebacterium parvum therapy on immunoglobulin class and IgG subclass levels in cancer patients. British Journal of Cancer. 1975; 32: 310-22.<\/span><br \/>\n<span style=\"font-size: 12pt;\">35. Alexandroff AB et al. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 1999; 353: 1689-94.<\/span><br \/>\n<span style=\"font-size: 12pt;\">36. Woorduff MFA, Forman B. Effect of antilymphocyte serum on suspensions of lymphocytes in vitro. Nature. 1951; 168: 35.<\/span><br \/>\n<span style=\"font-size: 12pt;\">37. Woorduff MFA, Forman B. Effect of antilymphocyte serum on suspensions of lymphocytes in vitro. Nature. 1951; 168: 35.<\/span><br \/>\n<span style=\"font-size: 12pt;\">38. Woodruff MFA, Anderson NA. Effect of lymphocyte depletion by thoracic duct fistula and administration of anti-lymphocyte serum on the survival of skin homografts in rats. Nature. 16 November, 1963: 200: 702.<\/span><br \/>\n<span style=\"font-size: 12pt;\">39. James K, Jubb VS. Effect of anti-rat lymphocyte antibody on humoral antibody formation. Nature. 1967; 215 (5099): 367-71.<\/span><br \/>\n<span style=\"font-size: 12pt;\">40. Woodruff MFA et al.. Transplantation of a kidney from an identical twin. Lancet. 10 June, 1961, pages 1245-9.<\/span><br \/>\n<span style=\"font-size: 12pt;\">41. Woodruff MFA et al.. Transplantation of a kidney from a brother to sister. British Journal of Urology. 1962; 34: 3-14.<\/span><br \/>\n<span style=\"font-size: 12pt;\">42. Woodruff MF et al. Renal transplantation in man. Experience in 35 cases. Lancet. 1969; 1: 6-12.<\/span><br \/>\n<span style=\"font-size: 12pt;\">43. Kingston A et al. Studies on the lymphocytes of patients with renal homografts. Transplantation. 1971; 12: 305-9.<\/span><br \/>\n<span style=\"font-size: 12pt;\">44. Woodruff MFA et al. Long survival after renal transplantation in man. British Journal of Surgery. 1976; 63: 85-101.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Innovations and research areas related to Renal Medicine or Transplantation in Edinburgh in the 1960s to 1990s New inventions: 1961 Fluon arterio-venous shunt for repeated haemodialysis, by Mr I Sinclair, Mr M Henderson and Dr D Simpson (Sinclair et al, 1961) 1964 Regional heparinisation developed by Dr Howard Davies, haematologist\u2026<\/p>\n<p> <a class=\"continue-reading-link\" href=\"https:\/\/edren.org\/ren\/unit\/history\/innovations-and-research\/\"><span>Continue reading<\/span><i class=\"crycon-right-dir\"><\/i><\/a> <\/p>\n","protected":false},"author":2,"featured_media":0,"parent":12,"menu_order":209,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"class_list":["post-2097","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/edren.org\/ren\/wp-json\/wp\/v2\/pages\/2097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/edren.org\/ren\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/edren.org\/ren\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/edren.org\/ren\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/edren.org\/ren\/wp-json\/wp\/v2\/comments?post=2097"}],"version-history":[{"count":3,"href":"https:\/\/edren.org\/ren\/wp-json\/wp\/v2\/pages\/2097\/revisions"}],"predecessor-version":[{"id":2501,"href":"https:\/\/edren.org\/ren\/wp-json\/wp\/v2\/pages\/2097\/revisions\/2501"}],"up":[{"embeddable":true,"href":"https:\/\/edren.org\/ren\/wp-json\/wp\/v2\/pages\/12"}],"wp:attachment":[{"href":"https:\/\/edren.org\/ren\/wp-json\/wp\/v2\/media?parent=2097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}